Navigation Links
Nephros Completes Bridge Financing and Announces Stockholder Rights Offering
Date:10/1/2010

he Nephros HDF system removes a range of harmful substances more effectively, and with greater capacity, than existing ESRD treatment methods, particularly with respect to substances known collectively as "middle molecules."  These molecules have been found to contribute to such conditions as dialysis-related amyloidosis, carpal tunnel syndrome, degenerative bone disease and, ultimately, mortality in the ESRD patient.  Nephros ESRD products are sold and distributed throughout Europe.

The Nephros Dual Stage Ultrafilter (DSU) is the basis for the Nephros line of water filtration products.  The patented dual stage cold sterilization ultrafilter has the capability to filter out bacteria and, due to its exceptional filtration levels, filter out many viruses, parasites and biotoxins.  Nephros's DSUs are being evaluated at several major U.S. medical centers for infection control.  The DSU has also been selected for further development by the U.S. Marine Corps for purification of drinking water by soldiers in the field.

For more information about Nephros, please visit the company's website at www.nephros.com.

Forward-Looking Statements

Statements in this news release that are not historical facts constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Such statements may be preceded by words such as "may," "plans," "expects," "believes," "hopes," "potential" or similar words. For such statements, Nephros claims the protection of the PSLRA.

Forward-looking statements are not guarantees of future performance, are based on assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond Nephros' control. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors that may cause such differences include the ri
'/>"/>

SOURCE Nephros, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Nephros Reports 2010 Second Quarter Financial Results
2. Nephros Receives Formal Response from FDA for 510(k) Application for Hemodiafiltration System
3. Nephros and AmeriWater Announce Dual Stage Ultrafilters to be a Standard Component of MRO Series Water Treatment Systems
4. Nephros Reports 2010 First Quarter Financial Results
5. Nephros Signs Development Agreement with STERIS
6. Nephros Signs Canadian Distribution Agreement with Bellco Health Care Inc.
7. Nephros Reports 2009 Third Quarter Financial Results
8. Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
9. Tigris Pharmaceuticals, Inc. Completes $6.5 Million Private Placement
10. Johnson & Johnson Completes Acquisition of Micrus Endovascular
11. Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Penwest Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... VIEW, Calif. , July 24, 2014 /PRNewswire/ ... a leading provider of medication and supply management ... a conference call Thursday, July 31, to discuss ... , Omnicell Second Quarter 2014 earnings conference ... 1:30 p.m. PTWho:  , Randall Lipps, chairman, president ...
(Date:7/24/2014)... and MENLO PARK, Calif. , July 24, ... ("DelMar" "the company") announced today that the company,s board of ... December 31 to June 30. Accordingly, DelMar will file a ... Jeffrey Bacha , president and CEO of DelMar ... step in achieving our goal of obtaining a senior exchange ...
(Date:7/24/2014)... , July 24, 2014 LSI Medience ... an Agreement with Kineticos, a Raleigh-Durham, ... Kineticos will support LSI Medience in identifying opportunities ... to demonstrate utility in clinical trials. ... utility in diagnosis of sepsis, prognosis of septic ...
Breaking Medicine Technology:Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 3LSI Medience Corporation and Kineticos Sign Agreement Related to the Presepsin Biomarker in Sepsis Management and Treatment 2
... , HUNTINGTON BEACH, California and ... cancer diagnostics, today announced the,inclusion of its breast cancer ... on the primary therapy of early breast,cancer. The recommendations ... will appear in the August print edition. , ...
... LAUSANNE, Switzerland, June 23 Debiopharm Group,(Debiopharm), ... on the development of prescription drugs that target unmet ... names Moapar(R),and Salvapar(R)), was launched in Germany in May ... was also launched on a preliminary basis in,Belgium. The ...
Cached Medicine Technology:Agendia's Breast Cancer Recurrence Test MammaPrint Included in International St. Gallen Expert Consensus Recommendations 2Salvacyl(R), Developed by Debiopharm, is Launched in two European Countries 2
(Date:7/25/2014)... (PRWEB) July 25, 2014 “You have a ... than 500 people and their loved ones across the U.S. ... a brain tumor diagnosis is typically met with confusion and ... new and difficult vocabulary, and make critical decisions about a ... tumor diagnosis is accompanied by a sense of isolation and ...
(Date:7/25/2014)... The North America Artificial lift market report defines ... analysis and forecast of revenue. The artificial lift market in ... in 2013 to around $7 billion by 2018, at a ... through the TOC of North America artificial lift market report, ... provides a glimpse of the segmentation in North America Artificial ...
(Date:7/25/2014)... Providence, RI (PRWEB) July 25, 2014 ... Island Quality Improvement Organization (QIO) was recently awarded ... from the Centers for Medicare & Medicaid Services ... to fourteen organizations across the United States, represent ... In order to successfully execute the contract initiatives, ...
(Date:7/25/2014)... Health Advocate™, Inc., the nation’s leading healthcare ... Corporation, is introducing its newest solution in an upcoming ... Quality. , The webinar will be held twice on ... at 2 PM ET. For more information or to ... or call 866.799.2655. , In an environment of escalating ...
(Date:7/25/2014)... July 25, 2014 -- The Elizabeth Glaser Pediatric ... between the Medicines Patent Pool (MPP) and Gilead ... fumarate (TAF), a promising new HIV medication. The ... Conference (AIDS 2014) in Melbourne, Australia. , ... trials, early data suggests it could be a ...
Breaking Medicine News(10 mins):Health News:American Brain Tumor Association to Expand Service Reach with Launch of Nationwide Volunteer Network 2Health News:American Brain Tumor Association to Expand Service Reach with Launch of Nationwide Volunteer Network 3Health News:North America Artificial Lift Services Market is Expected to Reach $7 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Artificial Lift Services Market is Expected to Reach $7 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Artificial Lift Services Market is Expected to Reach $7 Billion in 2018 - New Report by MicroMarket Monitor 4Health News:Healthcentric Advisors and Qualidigm Partner to Improve the Healthcare Quality for New England 2Health News:Healthcentric Advisors and Qualidigm Partner to Improve the Healthcare Quality for New England 3Health News:Healthcentric Advisors and Qualidigm Partner to Improve the Healthcare Quality for New England 4Health News:Health Advocate™, Inc., Holds Webinar to Introduce Provider-Centered Analytics 2Health News:Health Advocate™, Inc., Holds Webinar to Introduce Provider-Centered Analytics 3
... updated the NCCN Guidelines for Venous Thromboembolic Disease, which ... (PE), and is a common condition in people with ... graduated compression stockings in prophylaxis and treatment, and a ... May 20 The National Comprehensive Cancer Network (NCCN) ...
... Alliance designed to benefit Californians with medical ... Medical Association (CMA), representing 35,000 physicians in ... the MedicAlert Foundation, the leading nonprofit providing ... teamed up to provide patients living with ...
... counseling also proved cost-effective, study finds , , WEDNESDAY, ... program that promoted exercise, healthy eating and quitting ... to moderate chronic obstructive pulmonary disease (COPD) and ... patients in the study were randomly assigned to ...
... Market is Reflected in Burgeoning Pipeline of More than ... from Decision ResourcesWALTHAM, Mass., May 20 Decision Resources, ... for pharmaceutical and healthcare issues, finds that the launch ... over the next 10 years will drive the type ...
... partnership with Axway to provide innovative solutions ... technologists to address the challenges of implementing ... cost-effective manner.BELLEVUE, Wash., May 20 Edifecs, ... simplification and systems interoperability, and Axway, a ...
... Directors of BD (Becton, Dickinson and Company) (NYSE: ... per common share, payable on June 30, 2009 to holders ... rate is $1.32 per share. About BD BD is ... sells medical devices, instrument systems and reagents. The Company is ...
Cached Medicine News:Health News:NCCN Updates Supportive Care Guidelines for VTE 2Health News:NCCN Updates Supportive Care Guidelines for VTE 3Health News:California Medical Association Joins MedicAlert Foundation to Offer Medical Identification for Members and Patients 2Health News:Healthier Lifestyle Can Cut COPD Symptoms 2Health News:The Launch and Uptake of More Than 20 Novel Drugs Over The Next 10 Years Will Drive $12.5 Billion Growth in the Type 2 Diabetes Market 2Health News:Edifecs(TM) and Axway Announce a Partnership Targeting Innovative HIPAA 5010 Migration Solutions. 2Health News:Edifecs(TM) and Axway Announce a Partnership Targeting Innovative HIPAA 5010 Migration Solutions. 3Health News:Edifecs(TM) and Axway Announce a Partnership Targeting Innovative HIPAA 5010 Migration Solutions. 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: